Comparative data absent for many new drugs

Only about half of new drugs approved in the last decade had comparative effectiveness data available at the time of their FDA approval, and approximately two-thirds of new drugs had this information available when alternative treatment options existed, according to a study in the new issue of JAMA. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.